NXE0033744, an investigational oral EP4 receptor agonist discovered using Nxera’s NxWave™ drug discovery platform, is a potential first-in-class candidate for inflammatory bowel disease.
Tokyo, Japan and Cambridge, UK, 4 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) today announces that it has revised its consolidated financial forecast for the year ending 31 ...
Agreement reinforces Boehringer Ingelheim’s long-term commitment to China’s innovation ecosystem and validates SBP Group’s innovative R&D capabilities Ingelheim, Germany, and Hong Kong/China, 4 ...
Static electricity remains a major concern in manufacturing environments. Even when personnel, worktables, and floors are properly grounded, insulating materials can retain electrical charges for ...
ElderVoice Reports Its AI Phone Companion Alerted a Daughter After Her Mother Said She Was Panicking
ElderVoice works on the phone a parent already has. Families pick the days and times, and the companion calls. It chats about the day, gives gentle medication reminders and remembers things from ...
The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.
EAGLE, Idaho, Nov. 03, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, ...
Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ (PRnT) for the treatment of cancerous tumors, is pleased to announce continued expansion of its IsoPet ® ...
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the ...
Dagger ® is a trademark of Allogene Therapeutics, Inc.
VivoSim Labs, Inc. (Nasdaq: VIVS) (“VivoSim” or “Company”), a provider of AI-enabled New Approach Methodologies (NAMs) for preclinical safety, and Chemveda Life Sciences (“Chemveda”), an integrated ...
First nine months revenue of $82.9M, +41% year-over-year growth; IFRS gross margin of 76.1% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results